New Delhi: 17th February, 2026: The 23rd edition of BioAsia 2026, recognized as Asia’s leading life sciences and health tech forum, officially commenced today in Hyderabad. This milestone event brings together key stakeholders from across the globe, including leaders in biotechnology, pharmaceuticals, Medtech, digital health, research, investment, and policy. As the forum opens, it sets the stage for focused discussions on the integration of artificial intelligence, automation, and data sciences within the life sciences sector—paving the way for the next wave of healthcare innovation and the transformation.   Organized by the Government of Telangana, BioAsia has established itself over two decades as a global platform fostering collaboration, driving investment, and accelerating advancements across the entire life sciences value chain. This event underscores Telangana’s status as a leading hub for biopharma, biotechnology, vaccines, MedTech, and digital health, reinforcing its position as a global center for healthcare

Under the theme ‘TechBio Unleashed: AI, Automation, and the Biology Revolution,’ BioAsia 2026 underscores the integration of biology with artificial intelligence, automation, and data sciences. This convergence is revolutionizing drug discovery, diagnostics, therapies, biomanufacturing, and healthcare delivery, enabling faster, more accurate, and efficient solutions. The event focuses on translating scientific breakthroughs into tangible health outcomes, enhancing patient care, and fostering resilient healthcare systems. As Asia’s leading life sciences and health tech forum, the 23rd BioAsia gathers global leaders from biotechnology, pharmaceuticals, Medtech, digital health, research, investment, and policy to shape the future of healthcare innovation.

Bio Asia 2026  began with the inauguration of the International Exhibition and a formal opening ceremony led by Hon’ble Chief Minister Mr. A. Revanth Reddy, with senior leaders reaffirming Telangana’s leadership in life sciences and TechBio healthcare. At the ceremony, Prof. Bruce L. Levine, Barbara and Edward Netter Professor in Cancer Gene Therapay, Perelman School of Medicine at the University of Pennsylvania was presented with the Genome Valley Excellence Award for his pioneering work in Cancer therapies.

At Bio Asia 2026, major announcements were made by Opella Healthcare (France), Vaksindo Animal Health Pvt Ltd (division of JAPFA, Indonesia), Tredence Inc (USA), and Rx Propellant (RxP). The Swiss Pharmaceutical giant, Novartis unveiled a logo celebrating 25 years of its GCC presence in India with Hyderabad as its largest center globally outside its headquarters in Basel, Switzerland.

On the sidelines of the conference Hon’ble Chief minister met the leadership teams from Miltenyi Biotec, Sanofi, MSD, Takeda along with the Hon’ble Consul General of Indonesia and team from Vaksindo, Indonesia. The Hon’ble IT minister besides the meetings with the Hon’ble Chief Minister, he met with the leaders from NIBRT, Google DeepMind besides other engagements. These meetings were scheduled to help propel the life sciences eco-system in the state to forge relationships for the next generation of innovation driven growth in life sciences.

The day featured keynote addresses by Prof. Bruce L. Levine, Barbara and Edward Netter Professor in Cancer Gene Therapay, Perelman School of Medicine at the University of Pennsylvania, Dr. Howard Y. Chang, Chief Scientific Officer and SVP Global Research, Amgen, USA on advanced research and next-generation therapies. Besides the plenary address by Mr. Pushmeet Kohli, VP of Science, Google DeepMind, UK focusing on role of AI in bio medical discovery and drug development. The day will feature discussions by Industry leaders on AI, automation, and data sciences transforming drug development, manufacturing, and supply chains. Sessions focused on scaling innovation from lab to bedside, driving growth amid global challenges, and advancing biologics from discovery to clinical proof and CMC readiness. The discussions also revolved around the next gen CRDMO’s where AI would act as a force multiplier across the value chain. The day concluded with the CEO Conclave a discussion where Pharma Industry Leaders opined on the future of pharma and biotech through 2030, highlighting the growth, innovation, technology advancements, geopolitics and resilience shaping the competitiveness across the industry.

Shri A. Revanth Reddy, Hon’ble Chief Minister of Telangana, said, “Telangana has established itself as a global leader in life sciences, pharmaceuticals, and healthcare. The Next Gen Life Sciences Policy 2026-30 emphasizes that future growth will be driven by cross-border collaboration, international capital, and shared innovation. This reflects the state's dedication to innovation and excellence. Telangana is developing a future-ready ecosystem that transforms scientific breakthroughs into practical healthcare solutions for India and the global community. This strategy aims to foster sustainable economic growth and reinforce the state's leadership in the global life sciences sector. BioAsia 2026 offers a strategic platform for industry leaders to discuss emerging trends and challenges, shaping future business opportunities. The event also encourages stakeholders to explore how Telangana’s vibrant life sciences ecosystem can enhance patient outcomes worldwide, fostering innovation and collaboration across borders.”

Shri D. Sridhar Babu, Hon’ble Minister for IT, Electronics and Communications, and Industries and Commerce, Government of Telangana, said, “BioAsia 2026 stands as a premier platform uniting leading experts in healthcare and life sciences to explore innovative pathways for industry growth. This event underscores Telangana's vision to catalyze industry advancement and establish a robust ecosystem that attracts global investments and talent, reinforcing its status as a key player in the global life sciences landscape. Telangana is committed to positioning itself as a preferred global hub for life sciences, leveraging strategic initiatives and collaborative efforts to foster innovation, research, and development. The state’s new life sciences policy emphasizes frontier science and advanced manufacturing, including cell and gene therapies, peptides, and precision fermentation. It aims to bolster the ecosystem in clinical research, pharma services, diagnostics, medical electronics, and digital health, positioning Telangana as a global destination for life sciences investment. Telangana is preparing its workforce, industry and institutions to lead in the next wave of life sciences and healthcare innovation. These initiatives foster collaborations that accelerate drug discovery, diagnostics, healthcare delivery, and digital health innovations. Telangana remains committed to translating innovation into impactful healthcare solutions and driving economic growth, establishing itself as a preferred global hub for life sciences and healthcare advancements.”

Shri Sanjay Kumar, IAS, Special Chief Secretary, Industries and Commerce and ITE and C Departments, Government of Telangana, said, “BioAsia 2026 shows Telangana’s commitment to being at the forefront of the TechBio revolution. As biology converges with artificial intelligence and automation, the state is designing policies, infrastructure and regulatory frameworks that enable sustainable growth and global competitiveness. The Telangana Life Sciences team is facilitating partnerships, supporting advanced manufacturing and ensuring that emerging technologies are effectively translated into real-world healthcare solutions. This edition of BioAsia provides a platform to identify opportunities, address challenges and create actionable pathways for research, development and investment. By combining foresight, structured policy and robust support systems. This reinforces Telangana’s position as a trusted global partner in the rapidly evolving TechBio landscape.”

Shri Shakthi M. Nagappan, CEO, Telangana Life Sciences, said, “As the life sciences sector rapidly evolves, BioAsia 2026 marks a pivotal moment where artificial intelligence, automation, and data sciences intersect with biology to transform healthcare and biotech. Telangana’s commitment to fostering innovation and translational research ensures scientific insights translate into practical solutions. These initiatives boost economic growth, enhance patient outcomes, and position Hyderabad as key players in the dynamic TechBio industry.”

Investments announced at Bio Asia 2026: (Brief Summary)

Opella Healthcare, a global consumer healthcare company, spun off from Sanofi, with its global headquarters in France, and is expanding its GCC operations in a 42,000 sq. ft. facility, creating up to 500 jobs within the next year.

Vaksindo Animal Health Pvt Ltd: a division of JAPFA Indonesia, is establishing a state-of-the-art BSL-3 vaccine manufacturing facility in Genome Valley. The facility will focus on producing vaccines for poultry, cattle, swine, and aquaculture.

Tredence Inc is an AI and data science company, is announcing its Hyderabad operations as a dedicated innovation hub focused on AI-driven healthcare and life sciences analytics. The facility will span approximately 18,000 sq. ft. and support its global operations.

Rx Propellant (RxP) to develop a new, large-format life sciences campus in Genome Valley, Hyderabad as part of its long-term commitment to strengthening India’s life sciences ecosystem. The project will comprise over 1 million square feet of advanced laboratory infrastructure spread across ~12 acres of site delivered in phases over the next six years.